A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

Summary

This study evaluates the efficacy and safety of THX-110 in the management of tics and other symptoms (e.g. rage attacks, anxiety, depression, sleep difficulties) in patients with Tourette syndrome. In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. After completion of the first study part, patients will have the opportunity to continue into the second part of the study. In this part, all participants will receive THX-110.

Timeline

Start

2018-08

Primary completion

2019-11

Completion

2019-11

Drugs

Indications